Metropolis Healthcare Reports Strong Q1FY27 Performance with Revenue Reaching ₹450 Crore
Metropolis Healthcare Limited, India's second-largest pathology laboratory chain, announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a significant increase in revenue and improved operating profitability during the first quarter of the financial year 2027.The healthcare diagnostics firm saw revenue from operations climb to ₹450.2 crore, marking a strong performance. Concurrently, EBITDA for the quarter stood at ₹113.2 crore, reflecting robust growth across key segments and operational efficiencies.
Q1FY27 Operational Highlights
Metropolis reported sustained demand reflected in patient volume growing 10% year-over-year (YoY). Test volume also increased by 11% YoY.The company’s revenue streams showed varied growth rates:
- B2C revenue grew by 18% YoY, attributed to expanding digital engagement and targeted micro-marketing efforts, supported by the brand's strong pull.
- B2B revenue saw a 15% increase YoY, driven by an improved business quality and a wider network of clinicians and institutions.
Segment performance strengthened within specialized diagnostics. TruHealth revenue grew 22% YoY to INR 81 crore (representing 18% of the segment mix). Specialty revenue increased 17% YoY to INR 178 crore, accounting for 40% of the segment mix. The portfolio also witnessed high growth in premium offerings, with premium TruHealth packages growing over 50%, and radiology-integrated wellness packages increasing by more than 40%.
At a micro level, Revenue per Patient (RPP) increased 6% YoY, while Revenue per Test (RPT) improved by 5% YoY. This improvement was linked to a richer test mix and higher contributions from specialized diagnostics.
Geographic performance highlighted Tier III cities as fastest-growing markets, with revenue increasing around 25% YoY. These figures contrast against 11% growth in Tier I cities and 14% growth in Tier II cities, indicating significant growth opportunities beyond major metropolitan areas.
Financial Snapshot (Q1FY27)
The financial health of the company reflects disciplined execution and a scalable operating model. A key achievement noted was a 210 basis point expansion in EBITDA margin for Q1FY27 compared to the previous year.Financial results are summarized below:
| Financial Results Snapshot - Q1FY27 | Q1FY27 | Q1FY26 | Y-o-Y |
|---|---|---|---|
| Revenue from operations (In INR Crs.) | 450.2 | 386.1 | 16.6% |
| EBITDA (In INR Crs.) | 113.2 | 89.1 | 27.1% |
| EBITDA Margin (%) | 25.2% | 23.1% | 210 bps |
| Profit After Tax (In INR Crs.) | 56.9 | 45.2 | 25.8% |
| PAT Margin (%) | 12.6% | 11.7% | 90 bps |
Management Commentary
Ms. Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare Limited, stated that the diagnostics industry is consolidating around trusted, science-led providers as patients prioritize quality and specialized care. She noted that Q1 saw 17% revenue growth achieved through higher volumes without any price increase. "Our investments in scientific innovation, strategic acquisitions and network expansion continue to strengthen Metropolis' leadership across key markets," Ms. Shah commented, emphasizing the focus on making high-quality diagnostics accessible while creating sustainable long-term value.Mr. Surendran Chemmenkotil, Managing Director of Metropolis Healthcare Limited, added that the strong start reflects disciplined execution and business resilience. He noted that continued momentum in Specialty diagnostics and TruHealth confirms the strength of the company’s portfolio, reinforcing their focus on operational excellence and profitable growth.
METROPOLIS Stock Price Movement
Metropolis Healthcare Limited shares today slipped by 1.10%, settling at ₹584.5 after market close. The stock recorded a volume of 165,890 shares for the trading day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: